Literature DB >> 26563222

Mortality Risk of Hypnotics: Strengths and Limits of Evidence.

Daniel F Kripke1,2.   

Abstract

Sleeping pills, more formally defined as hypnotics, are sedatives used to induce and maintain sleep. In a review of publications for the past 30 years, descriptive epidemiologic studies were identified that examined the mortality risk of hypnotics and related sedative-anxiolytics. Of the 34 studies estimating risk ratios, odds ratios, or hazard ratios, excess mortality associated with hypnotics was significant (p < 0.05) in 24 studies including all 14 of the largest, contrasted with no studies at all suggesting that hypnotics ever prolong life. The studies had many limitations: possibly tending to overestimate risk, such as possible confounding by indication with other risk factors; confusing hypnotics with drugs having other indications; possible genetic confounders; and too much heterogeneity of studies for meta-analyses. There were balancing limitations possibly tending towards underestimates of risk such as limited power, excessive follow-up intervals with possible follow-up mixing of participants taking hypnotics with controls, missing dosage data for most studies, and over-adjustment of confounders. Epidemiologic association in itself is not adequate proof of causality, but there is proof that hypnotics cause death in overdoses; there is thorough understanding of how hypnotics euthanize animals and execute humans; and there is proof that hypnotics cause potentially lethal morbidities such as depression, infection, poor driving, suppressed respiration, and possibly cancer. Combining these proofs with consistent evidence of association, the great weight of evidence is that hypnotics cause huge risks of decreasing a patient's duration of survival.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26563222     DOI: 10.1007/s40264-015-0362-0

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  78 in total

Review 1.  Parachute use to prevent death and major trauma related to gravitational challenge: systematic review of randomised controlled trials.

Authors:  Gordon C S Smith; Jill P Pell
Journal:  BMJ       Date:  2003-12-20

Review 2.  Mendelian randomization studies: a review of the approaches used and the quality of reporting.

Authors:  Anna G C Boef; Olaf M Dekkers; Saskia le Cessie
Journal:  Int J Epidemiol       Date:  2015-05-06       Impact factor: 7.196

3.  Does the Prescription of Anxiolytic and Hypnotic Drugs Increase Mortality in Older Adults?

Authors:  Juliette Pinot; Marie Herr; Jean-Marie Robine; Philippe Aegerter; Jean-Jacques Arvieu; Joel Ankri
Journal:  J Am Geriatr Soc       Date:  2015-06       Impact factor: 5.562

4.  Association between hypnotics use and increased mortality: causation or confounding?

Authors:  C Ineke Neutel; Helen L Johansen
Journal:  Eur J Clin Pharmacol       Date:  2015-04-07       Impact factor: 2.953

5.  Sales of tranquillizers, hypnotics/sedatives and antidepressants and their relationship with underprivileged area score and mortality and suicide rates.

Authors:  J Sundquist; A Ekedahl; S E Johansson
Journal:  Eur J Clin Pharmacol       Date:  1996       Impact factor: 2.953

Review 6.  Meta-analyses of hypnotics and infections: eszopiclone, ramelteon, zaleplon, and zolpidem.

Authors:  Florendo L Joya; Daniel F Kripke; Richard T Loving; Arthur Dawson; Lawrence E Kline
Journal:  J Clin Sleep Med       Date:  2009-08-15       Impact factor: 4.062

7.  Increased risk of ischaemic heart disease mortality in elderly men using anxiolytics-hypnotics and analgesics. Results of the 10-year follow-up of the prospective population study "Men born in 1914", Malmo, Sweden.

Authors:  J Merlo; B Hedblad; M Ogren; J Ranstam; P O Ostergren; A Ekedahl; B S Hanson; S O Isacsson; H Liedholm; A Melander
Journal:  Eur J Clin Pharmacol       Date:  1996       Impact factor: 2.953

8.  Ethanol drug interaction with chlordiazepoxide and pentobarbital.

Authors:  M Okamoto; S N Rao; L M Aaronson; J L Walewski
Journal:  Alcohol Clin Exp Res       Date:  1985-12       Impact factor: 3.455

Review 9.  Comparative effectiveness of cognitive behavioral therapy for insomnia: a systematic review.

Authors:  Matthew D Mitchell; Philip Gehrman; Michael Perlis; Craig A Umscheid
Journal:  BMC Fam Pract       Date:  2012-05-25       Impact factor: 2.497

10.  Network Mendelian randomization: using genetic variants as instrumental variables to investigate mediation in causal pathways.

Authors:  Stephen Burgess; Rhian M Daniel; Adam S Butterworth; Simon G Thompson
Journal:  Int J Epidemiol       Date:  2014-08-22       Impact factor: 7.196

View more
  17 in total

1.  The Quest for Mindful Sleep: A Critical Synthesis of the Impact of Mindfulness-Based Interventions for Insomnia.

Authors:  Sheila N Garland; Eric S Zhou; Brian D Gonzalez; Nicole Rodriguez
Journal:  Curr Sleep Med Rep       Date:  2016-07-05

2.  Mortality Following Nonfatal Opioid and Sedative/Hypnotic Drug Overdose.

Authors:  Sidra Goldman-Mellor; Mark Olfson; Cristina Lidon-Moyano; Michael Schoenbaum
Journal:  Am J Prev Med       Date:  2020-05-07       Impact factor: 5.043

3.  Sleep Quality and Sleep Duration with CKD are Associated with Progression to ESKD.

Authors:  Ryohei Yamamoto; Maki Shinzawa; Yoshitaka Isaka; Etsuko Yamakoshi; Enyu Imai; Yasuo Ohashi; Akira Hishida
Journal:  Clin J Am Soc Nephrol       Date:  2018-11-15       Impact factor: 8.237

4.  Patient Preferences for Managing Insomnia: A Discrete Choice Experiment.

Authors:  Janet M Y Cheung; Delwyn J Bartlett; Carol L Armour; Bandana Saini; Tracey-Lea Laba
Journal:  Patient       Date:  2018-10       Impact factor: 3.883

5.  Predicting Future Self-Reported Motor Vehicle Collisions in Subjects with Primary Open-Angle Glaucoma Using the Penalized Support Vector Machine Method.

Authors:  Kenya Yuki; Ryo Asaoka; Sachiko Awano-Tanabe; Takeshi Ono; Daisuke Shiba; Hiroshi Murata; Kazuo Tsubota
Journal:  Transl Vis Sci Technol       Date:  2017-06-02       Impact factor: 3.283

Review 6.  Pharmacological Management of Insomnia.

Authors:  Sarika Madari; Raphael Golebiowski; Meghna P Mansukhani; Bhanu Prakash Kolla
Journal:  Neurotherapeutics       Date:  2021-02-01       Impact factor: 7.620

Review 7.  Hypnotic drug risks of mortality, infection, depression, and cancer: but lack of benefit.

Authors:  Daniel F Kripke
Journal:  F1000Res       Date:  2016-05-19

8.  Patterns of zolpidem use among Iraq and Afghanistan veterans: A retrospective cohort analysis.

Authors:  Ramona Shayegani; Kangwon Song; Megan E Amuan; Carlos A Jaramillo; Blessen C Eapen; Mary Jo Pugh
Journal:  PLoS One       Date:  2018-01-23       Impact factor: 3.240

9.  What do hypnotics cost hospitals and healthcare?

Authors:  Daniel F Kripke
Journal:  F1000Res       Date:  2017-04-21

10.  Does a Consumer-Targeted Deprescribing Intervention Compromise Patient-Healthcare Provider Trust?

Authors:  Yi Zhi Zhang; Justin P Turner; Philippe Martin; Cara Tannenbaum
Journal:  Pharmacy (Basel)       Date:  2018-04-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.